Loading...
Back to narrative

AKBA: European Partnership And Clinical Data Will Drive Substantial Upside

AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside

AKBA logo
AKBA
AnalystConsensusTarget
Not Invested
Published 28 Apr 2025

Update shared on 28 Nov 2025

Fair value Decreased 1.82%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-13.9%
7D
1.9%

Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth.

What's in the News

  • Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe. Any resulting know-how or patent rights will be owned by Akebia Therapeutics (Client Announcements).
  • A new Phase 3 trial analysis presented at ASN Kidney Week 2025 showed Vafseo had favorable effects on reducing death and hospitalization compared to darbepoetin alfa for adults with CKD-related anemia on dialysis. Vafseo is approved only for patients on dialysis. Safety in non-dialysis patients is not established and its use is not recommended for them (Product-Related Announcements).
  • After discussions with the FDA, Akebia announced it will not pursue the VALOR clinical trial for vadadustat in non-dialysis CKD patients, citing regulatory requirements for a larger, more expensive trial. Vafseo remains unapproved and not recommended for anemia in CKD patients not on dialysis (Product-Related Announcements).

Valuation Changes

  • Consensus Analyst Price Target decreased slightly from $5.50 to $5.40.
  • Discount Rate increased modestly from 7.70% to 7.87%.
  • Revenue Growth improved from 17.31% to 18.08%.
  • Net Profit Margin rose significantly from 19.64% to 26.14%.
  • Future P/E decreased notably from 31.28x to 22.74x.

Have other thoughts on Akebia Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.